(Q39958805)

English

A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

human pregnancy

1 reference

based on heuristic

inferred from title

pregnant person

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Geert Leroux-Roels

1

object named as

Geert Leroux-Roels

0 references

object named as

Cathy Maes

2

0 references

9

object named as

Karen Slobod

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

author name string

Julie Willekens

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Fien De Boever

4

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Richard de Rooij

5

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Leah Martell

6

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Lisa Bedell

7

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Frederick Wittke

8

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Peter Dull

10

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

language of work or name

0 references

publication date

26 February 2016

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1786-1791

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Changing epidemiology of group B streptococcal colonization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

An overview of global GBS epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Neonatal sepsis: an old problem with new insights

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Bacterial meningitis in the United States, 1998-2007.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Group B streptococcal disease in infants: progress in prevention and continued challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

The spectrum of perinatal group B streptococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Group B streptococcus late-onset disease: 2003-2010.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Maternal antibody at delivery protects neonates from early onset group B streptococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Preventing newborn infection with maternal immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Epidemiology of Invasive Group B Streptococcal Disease in the United States, 1999-2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine: A Randomized Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Revisiting the Need for Vaccine Prevention of Late-Onset Neonatal Group B Streptococcal Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

A maternal vaccine against group B Streptococcus: past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.044

7 January 2021

Identifiers

10.1016/J.VACCINE.2016.02.044

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39958805&oldid=1881259320"